CN101933919B - Application of brown cyanidin - Google Patents
Application of brown cyanidin Download PDFInfo
- Publication number
- CN101933919B CN101933919B CN2010102236966A CN201010223696A CN101933919B CN 101933919 B CN101933919 B CN 101933919B CN 2010102236966 A CN2010102236966 A CN 2010102236966A CN 201010223696 A CN201010223696 A CN 201010223696A CN 101933919 B CN101933919 B CN 101933919B
- Authority
- CN
- China
- Prior art keywords
- cyanidin
- purposes
- brown
- blood fat
- brown cyanidin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Abstract
The invention discloses application of brown cyanidin in preparing a medicament for treating high blood fat diseases, in particular a medicament for treating high blood fat diseases of high triglyceride and high serum low-density protein types. The applicant discovers that the brown cyanidin has remarkable curative effect. Meanwhile, the invention also provides a preparation for treating the diseases.
Description
Technical field
The invention discloses brown cyanidin and prepare the purposes of blood lipid-lowering medicine, belong to field of medicaments as unique active component.
Background technology
Medical research shows; Lipid metabolism is the main cause that causes cardiovascular and cerebrovascular disease; Hyperlipidemia is to cause atherosclerotic one of the main reasons among this; Particularly the serum triglycerides rising is to cause atherosclerotic significant indexes, therefore reduces the main means that serum triglyceride level is the treatment hyperlipidemia.
Herba Eupatorii Lindleyani is a herbaceos perennial, and the Compositae Eupatorium can all herbal medicine. contained main component is flavonoid, alkaloid, volatile oil, coumarin etc., is used for the clearing away lung-heat to relieve cough effects such as antiviral of relievining asthma traditionally, and extensive utilization is arranged clinically.
Contain a large amount of different chemical constituents in the Herba Eupatorii Lindleyani; Research (the Qian Shihui etc. of flavones ingredient in the Herba Eupatorii Lindleyani; CHINA JOURNAL OF CHINESE MATERIA MEDICA, 2004.1) reported and contained astragaloside, brown cyanidin, kaempferol, Quercetin, Trifolin, hyperin in the Herba Eupatorii Lindleyani that Herba Eupatorii Lindleyani is to the preventive and therapeutic effect (Zhou Yuanda etc. of the experimental hyperlipidemia of big mice; China Dispensary 2007.18.3) has reported that Herba Eupatorii Lindleyani has certain curative effect aspect the treatment hyperlipidemia disease.One Chinese patent application 2006100009181 discloses the application of Herba Eupatorii Lindleyani in the treatment hyperlipidaemic conditions; But do not study the effect of the concrete treatment hyperlipidemia of the various compositions of Herba Eupatorii Lindleyani, do not relate to the effect of Herba Eupatorii Lindleyani aspect the hyperlipidemia of treatment various factors yet.
To sum up content has been carried out preliminary study although Herba Eupatorii Lindleyani is treated hyperlipidemia in the prior art, and wherein contained brown cyanidin is used for the effect of blood fat reducing and does not see relevant report.
Summary of the invention
The applicant is in the process of research Herba Eupatorii Lindleyani pharmacologically active; Find that brown cyanidin treatment hyperlipidaemic conditions is wherein had good result; Especially treat high triglyceride and high serum low-density protein type hyperlipidemia has significant effect. based on this discovery; The applicant is used to prepare the purposes of blood lipid-lowering medicine with brown cyanidin, is applied to triglyceride reducing further, reduces the purposes of serum low-density protein drug.
The medicine of blood fat reducing purposes according to the invention is meant the one type of goods general name that therapeutic effect is arranged with blood fat reducing effect on being of universal significance, and includes but not limited to medicine, health product, nutriment.
The medicine of purposes according to the invention includes but not limited to tablet, injection, injectable powder, capsule, granule.
The medicine of purposes according to the invention; Can be that brown cyanidin and acceptable accessories adopt conventional preparation process to process particular dosage form, can brown cyanidin and excipient substance be processed medicament through the experimental technique of routine to those skilled in the art.Described adjuvant can be a disintegrating agent, includes but not limited to hydroxypropyl starch, hydroxypropyl cellulose, carboxymethyl starch sodium, carboxymethylcellulose calcium, polyvinylpolypyrrolidone etc.; Can be filler, include but not limited to lactose, sucrose, mannitol, microcrystalline Cellulose, dextrin, starch etc.; Can be wetting agent or binding agent, include but not limited to gelling starch, polyvidone, sodium carboxymethyl cellulose etc.; Can be lubricant, include but not limited to magnesium stearate, micropowder silica gel, Macrogol 4000, polyethylene glycol 6000 etc.;
The medicine of purposes according to the invention, formulation method is not restricted, and can be any adoptable preparation process of pharmaceutical field.
The medicine of purposes according to the invention can adopt different medications according to himself characteristic, for example can adopt the method for oral administration, and its preparation formulation can be tablet, capsule, soft capsule, oral liquid, suspension; Also can adopt the parenteral approach, its preparation formulation can be injection solution, suspension for injection etc.
The pharmacological evaluation that the inventor carries out shows that brown cyanidin has the effect of significant blood fat reducing, especially has the effect of extremely significant triglyceride reducing and serum low-density LP.Therefore be applied to treat and/or prevent hyperlipidemia on the clinical drug of purposes according to the invention, especially be applied to treat and/or prevent high triglyceride and serum low-density LP blood fat disease.
The specific embodiment
Following embodiment only is used to provide the concrete preparation way of realizing purposes of the present invention, is not limited to the implementation method of purposes of the present invention.
Among the present invention; The palm fibre cyanidin can adopt following method to extract: after Herba Eupatorii Lindleyani plant drying and crushing; Extract twice through 95% alcohol heating reflux; Each heating two hours extracts gained extractum four times behind the recovery ethanol in ethyl acetate, adopt recrystallization method to obtain brown cyanidin then.
Also can directly buy brown cyanidin chemical compound; Used brown cyanidin is bought to spread out from Shanghai and is won Industrial Co., Ltd. among the following embodiment of the present invention; Through detecting its purity is 98.5%. lindley eupatorium herb general flavone extract; Purchase in Ange Pharmaceutical Co., Ltd, Jiangsu, purity is that 96%. brown cyanidin content are 15%.
Embodiment 1: the preparation of brown cyanidin tablet
Prepare brown cyanidin tablet according to following consumption
Palm fibre cyanidin 5g
Sucrose 100g
Starch 30g
Magnesium stearate 0.5g
Sodium carboxymethyl cellulose 30g
Brown cyanidin mixed forming uniform mixture with sucrose, starch, add an amount of water and powder is granulated.After the drying granule sieved and mix, then tabletting with all the other adjuvants.
Embodiment 2: the particulate preparation of brown cyanidin
Palm fibre cyanidin 5g
Dextrin 25g
Starch 10g
50% ethanol is an amount of
Dextrin, starch are crossed 100 mesh sieves respectively, and with brown cyanidin, dextrin, starch mix homogeneously, ethanol joins mixing in the said mixture, processes granule.
The preparation of embodiment 3 brown cyanidin Emulsions
Palm fibre cyanidin 1g
Soybean oil 20g
Vitamin E 0.8g
Lecithin 2g
Glycerol 2.5g
Water adds to 1000ml
Lecithin, glycerol is scattered in the 800ml water forms water.
Brown cyanidin, vitamin E are joined mix homogeneously formation oil phase in the soybean oil.
Water and oil phase join aqueous phase with oil phase after being preheated to 70 degree respectively, and the even colostrum that gets of high-speed stirred is with the back packing sterilization of the even breast of high pressure homogenization machine.
Embodiment 4 brown cyanidin oral liquids
Palm fibre cyanidin 5g
Mel 30g
Sorbic acid 5g
Fructus Lycii acid sodium 5g
Essence 1ml
Water is an amount of
Each component of above-mentioned amount after the mixing and stirring dissolving, is sealed the bottle oral liquid according to specific standard in water.
Embodiment 5: brown cyanidin injection
Palm fibre cyanidin 3g
Sodium sulfite 20g
Disodium edetate 5g
Water for injection is to 1000ml
Brown cyanidin, sodium sulfite, disodium edetate are joined mix homogeneously in the water for injection respectively, and sterilization back branch is filled to cillin bottle.
Pharmacodynamics test one:
Material and articles for use: brown cyanidin, lindley eupatorium herb general flavone, lovastatin.
Method: the KM mice, male and female half and half, totally 70, random packet is: first group: model control group; Second group: the blank group; The 3rd group: low dosage palm fibre cyanidin group; The 4th group: middle dosage palm fibre cyanidin group; The 5th group: high dose palm fibre cyanidin group; The 6th group: the lovastatin positive controls; The 7th group: the lindley eupatorium herb general flavone positive controls.
Except the blank group, other each treated animals are all with the modeling of hyperlipidemia diet: high fat materials such as 10% cholesterol, 20% Adeps Sus domestica, 2% cholate, 1% propylthiouracil, 10% sucrose are prepared into Emulsion with 15% tween, 5% propylene glycol.The modeling mice is irritated the high lipoprotein emulsion 0.5ml/g of clothes the morning, receives reagent thing 0.2mg/10g afternoon separately.Blank group and model control group all give distilled water contrast, modeling continuously.After the administration 14 days, stop modeling, successive administration is 7 days then, and next day is got blood in drug withdrawal, measures serum triglycerides (TC), serum cholesterol (TG).
Experimental result: the result according to following table 1 can find out that serum TC, TG all raise after the mice modeling, and the modeling success is described.
Lovastatin and lindley eupatorium herb general flavone extract can reduce the TC of hyperlipidemia model animal, but the lindley eupatorium herb general flavone extract does not have effect to reducing TG.
Each administration group of palm fibre cyanidin all demonstrates good effect for reducing blood fat, especially TC is had significant reduction effect, and wherein middle high dose group effect is especially obvious.The while data show, high dose group also produces effect to reducing TG in the brown cyanidin.
Table 1 different pharmaceutical is to the influence of mice serum blood fat
(* p＜0.05, expression is compared with the blank group, and model group has on the statistics to be distinguished; Δ p＜0.05, Δ Δ p＜0.01, Δ Δ Δ p＜0.001 is represented respectively to compare with model group, has difference, significantly difference, extremely significantly difference on the statistics)
Pharmacodynamics test two
Laboratory animal: Carnis Coturnicis japonicae, male, body weight 100 ± 10g, raises after being divided into 7 groups at random totally by 70.
Feedstuff: adopted 0.12: 12: 12: 12: 0.004: 76 ratio is mixed cholesterol, Adeps Sus domestica, yolk powder, propylthiouracil, normal feedstuff; Wherein the cholesterol of per unit feedstuff employing is 36g; Evenly be divided into 300 parts, to the amount feeding of every Carnis Coturnicis japonicae according to portion/sky.Method according to test one adopts amount grouping modeling in the following table, and is preceding all around respectively in modeling in the morning, the administration in afternoon; Be the administration in afternoon around the back.
Detect index: the 8th all administrations finish the back and get blood in Carnis Coturnicis japonicae antetheca vein place next day, measure TC, TG, LDL-C (serum low-density LP), HDL-C (serum high-density LP) content in the serum.
Experimental result: can find out that from following data the brown cyanidin of middle high dose all can obviously reduce the content of serum cholesterol, serum triglycerides, serum low-density LP, obviously the content of high density lipoprotein increasing.Under the Isodose, brown cyanidin effect all is superior to the lindley eupatorium herb general flavone extract.
Table 2 different pharmaceutical is to the influence of Carnis Coturnicis japonicae serum albumin
(* p＜0.05, expression is compared with blank control group, and model has significant difference; Δ p＜0.05, expression is compared with model group, has significant difference)
Claims (8)
1. brown cyanidin is used for preparing the purposes of blood lipid-lowering medicine as unique active component.
2. according to the purposes of claim 1, said blood fat reducing is to reduce serum cholesterol.
3. according to the purposes of claim 1, said blood fat reducing is to reduce serum triglycerides.
4. according to the purposes of claim 1, said blood fat reducing is to reduce serum low-density LP.
5. according to the purposes of claim 1, said blood fat reducing is the rising serum high-density LP.
6. according to the purposes of above-mentioned arbitrary claim, said blood lipid-lowering medicine is to be unique active component with brown cyanidin, adds the preparation that pharmaceutic adjuvant is processed.
7. according to the purposes of claim 6, said blood lipid-lowering medicine is an oral formulations.
8. according to the purposes of claim 6, said blood lipid-lowering medicine is a parenteral formulations.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102236966A CN101933919B (en) | 2010-07-01 | 2010-07-01 | Application of brown cyanidin |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2010102236966A CN101933919B (en) | 2010-07-01 | 2010-07-01 | Application of brown cyanidin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN101933919A CN101933919A (en) | 2011-01-05 |
| CN101933919B true CN101933919B (en) | 2012-04-18 |
Family
ID=43387643
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN2010102236966A Active CN101933919B (en) | 2010-07-01 | 2010-07-01 | Application of brown cyanidin |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN101933919B (en) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103310107A (en) * | 2013-06-24 | 2013-09-18 | 浪潮电子信息产业股份有限公司 | Method for evaluating energy efficiency of data center infrastructure |
| CN103655545B (en) * | 2013-12-02 | 2016-03-02 | 滨州医学院 | The application of Jaceosidin in the medicine preparing treatment or preventing chronic injury of kidney |
| CN103655544B (en) * | 2013-12-02 | 2016-03-30 | 滨州医学院 | The application of Jaceosidin in preparation prevention or the Fibrotic medicine for the treatment of chronic hepatic injury regulating liver-QI |
| CN103655546B (en) * | 2013-12-02 | 2016-03-30 | 滨州医学院 | Jaceosidin prevents in preparation or treats the application in the medicine of pulmonary fibrosis |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE277613T1 (en) * | 1995-12-26 | 2004-10-15 | Suntory Ltd | ANTI-OBESITY AGENTS CONTAINING PROCYANIDIN AS THE ACTIVE INGREDIENTS |
| JP2003252766A (en) * | 2002-02-28 | 2003-09-10 | Sanei Gen Ffi Inc | Antiobesity and/or antidiabetic agent containing cyanidin 3-glucoside as active component |
| US20060234957A1 (en) * | 2003-03-03 | 2006-10-19 | Takanori Tsuda | Adiponectin expression promoter |
| CN1202834C (en) * | 2003-09-04 | 2005-05-25 | 江苏省中医药研究院 | Application of the effective part of Chinese medicinal material lindley eupatorium herb in preparing antiviral medicine |
| CN100515230C (en) * | 2006-01-12 | 2009-07-22 | 重庆佳易医疗器械有限公司 | New medicinal use of eupatorium lindleyanun |
| CN101735188B (en) * | 2008-11-12 | 2012-07-04 | 上海奥博生物医药技术有限公司 | Method for synthesizing brown cyanidin, hispidulin and herba lycopi flavone |
-
2010
- 2010-07-01 CN CN2010102236966A patent/CN101933919B/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CN101933919A (en) | 2011-01-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN104383123A (en) | Method for preparing golden camellia lipid-lowering blood sugar-reducing preparation | |
| CN101933919B (en) | Application of brown cyanidin | |
| CN103083557A (en) | Traditional Chinese medicine composition with functions of reducing blood pressure and blood fat | |
| CN105832794A (en) | Application of Gynura procumbens to production of medicine, healthcare food or functional food for preventing and treating hyperuricemia | |
| CN103372051B (en) | Red rice and kudzuvine root medicinal composition for regulating blood fat and preparation method of the composition | |
| CN1947747B (en) | Traditional Chinese medicine composition containing luteolin and capsule of sweeping forsythia and its preparation method and use | |
| CN1951422A (en) | Pharmaceutical composition for treating disease of liver and gallbladder system and preparation and use thereof | |
| CN102614280B (en) | Chinese medicinal composition with blood fat reducing effect, and preparation method and application thereof | |
| CN106535912B (en) | Control pharmaceutical composition and its application of human body blood fat and body weight | |
| CN102552139B (en) | Oligomeric proantho cyanidins self-emulsifying system composition and application thereof | |
| CN109316565B (en) | Blood fat reducing composition and preparation method and application thereof | |
| CN100434091C (en) | Fenugreek seed extract and its preparing process and application | |
| CN101879157A (en) | Application of kaempferol | |
| CN101890035B (en) | Application of trifolin | |
| CN112089738A (en) | Preparation method and application of caulis sinomenii extract | |
| CN100364579C (en) | Oral medicine for treating hyperlipemia | |
| CN101890036B (en) | Application of astragaloside | |
| CN101161270B (en) | Pharmaceutical composition of cattail pollen and kudzu root | |
| CN103372114B (en) | Red rice and rhizoma alismatis medicinal composition for regulating blood fat and preparation method of composition | |
| CN101176769A (en) | Pharmaceutical composition of cattail pollen and red orpin | |
| CN100998777B (en) | Traditional Chinese medicine capsule for inducing sweat, cleaning damp and harmonizing middle-jaio, and its preparing method | |
| CN101167796B (en) | Monascus and red sage root composition for preventing and treating cardiovascular and cerebrovascular diseases | |
| CN111588777A (en) | Blood fat reducing wolfberry composition | |
| CN114533819A (en) | Traditional Chinese medicine composition for treating hyperlipidemia and preparation method and application thereof | |
| CN106138685B (en) | A kind of toxicant elimination and fat cleanness preparation and preparation method thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| C14 | Grant of patent or utility model | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address | ||
| CP03 | Change of name, title or address |
Address after: 210047 room 1203, building D, 606 ningliu Road, Changlu street, Jiangbei new district, Nanjing City, Jiangsu Province Patentee after: Nanjing century Bokang Pharmaceutical Technology Co., Ltd Address before: 100070 Beijing science and Technology Park of Fengtai Haiying Road No. 9 Jintang building 3 203 Patentee before: BEIJING CENTURY BIOCOM PHARMACEUTICAL TECHNOLOGY Co.,Ltd. |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20201230 Address after: 226300 1-2 / F, C6 building, 266 Century Avenue, Nantong hi tech Zone, Nantong City, Jiangsu Province Patentee after: JIANGSU REPODX BIOTECHNOLOGY Co.,Ltd. Address before: 210047 room 1203, building D, 606 ningliu Road, Changlu street, Jiangbei new district, Nanjing City, Jiangsu Province Patentee before: Nanjing century Bokang Pharmaceutical Technology Co., Ltd |